Poveda, A., Oaknin Benzaquen, A. M., Rubio, M. J., Guerra, E., Fariñas Madrid, L., Rodriguez Freixinos, V., . . . Redondo Sanchez, A. (2022). Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
Citación estilo ChicagoPoveda, Andres, Ana Mazaltob Oaknin Benzaquen, Maria Jesus Rubio, Eva Guerra, Lorena Fariñas Madrid, Victor Rodriguez Freixinos, Raquel López-Reig, y Andres Redondo Sanchez. Phase 2 Trial (POLA Study) of Lurbinectedin Plus Olaparib in Patients With Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. 2022.
Cita MLAPoveda, Andres, et al. Phase 2 Trial (POLA Study) of Lurbinectedin Plus Olaparib in Patients With Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. 2022.